Amarin Corporation plc · NASDAQ:AMRN
Amarin — Amarin Corp Plc\uk — Investor Presentation (November 2022)
15 slides from Amarin's investor presentation, Nov 16, 2022
Slide 1: November Investor Presentation
November Investor Presentation November 16, 2022 Karim Mikhail President & CEO Exhibit 99.1
Slide 2: Forward Looking Statements & Disclaimer
Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic pr
Slide 3: Amarin Growth Strategy
Amarin Growth Strategy Breadth - Geographic Expansion Stabilize the US o @ Launch in Europe ; © Expand Internationally
Slide 4: Amarin Maintaining ~60% Share in US Market
Source: Symphony Health Solutions, METYS Weekly Amarin Maintaining ~60% Share in US Market
Slide 5: Third Quarter 2022 Results
Third Quarter 2022 Results Total Revenue by Quarter OPERATIONAL INITIATIVES RESULTING IN LOWER CASH BURN Third quarter 2022 was CASH POSITIVE excluding restructuring charges Cost reduction plan in June on-track to reduce operating costs by approximately $100 MILLION THROUGH MID-2023 Efforts to reneg
Slide 6: Recent Initiatives Result in Lower Operating Expenses and Cash Burn
Recent Initiatives Result in Lower Operating Expenses and Cash Burn $95 $87 $19* $60 $ M’s * +$6M cash flow positive excluding $25M Q2'22 restructuring which was paid in Q3'22 $ M’s
Slide 7: Europe Progress To Date in 2022
Europe Progress To Date in 2022: Achieved national reimbursements in Sweden, England, Wales, Northern Ireland, and Finland and have obtained individual reimbursement in Denmark and Austria Launched in England and Wales as planned on October 13, 2022 Also making progress in additional key European ma
Slide 8: Continued Progress in Europe: Pricing & Reimbursement Decision and Launch Efforts
1. Regulatory Approval 2. Submission of Market Access & Reimbursement Dossiers 3. Scientific Evidence Assessm. / Recommendation 4. Reimbursement Price Negotiations 5. Country Launch Pricing announcement & Publication Austria* Denmark* England/Wales/Northern Ireland Finland France Germany** Italy Net
Slide 9: Plans to Bring Benefits of VASCEPA/VAZKEPA to 20 Additional Markets
Note: The company is pursuing expansion into these various additional markets and the status of regulatory and/or patent approval will vary market to market. Plans to Bring Unique Cardioprotective Benefits of VASCEPA/VAZKEPA to 20 Additional Markets 1ST WAVE 2022 UP TO Supported by REDUCE-IT Study a
Slide 10: Continued Presence, Key Data Featured at Global Congresses
Continued Presence, Key Data Featured at Global Congresses OCT 27-30th NOV 5-7th NOV 6-9th AUG 26-29th
Slide 11: Independent RESPECT-EPA Study Now Third to Underscore CV Risk Reduction Benefits
Independent RESPECT-EPA Study Now Third to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid Late breaking data presented at AHA using 1.8 grams per day of purified EPA is consistent with the substantial body of evidence from the REDUCE-IT and JELIS trials, which showed that highly puri
Slide 12: Progress and Achievements YTD 2022
US BUSINESS DEMONSTRATING ENCOURAGING TRENDS Recent stable prescription trends based on previous 17-plus weeks of trends* Quarterly revenue remains relatively stable Progress and Achievements YTD 2022 SIGNIFICANT PROGRESS ON CASH PRESERVATION INITIATIVES Cost savings plans to achieve $100 million in
Slide 13: Upcoming Drivers of Success
Upcoming Drivers of Success OPERATIONAL TRENDS CONTINUE TO IMPROVE CASH POSITION Maintaining stabilization of U.S. Business Reduce operational spending as outlined in cost savings plan Completion of additional cash preservation initiatives to continue to reduce cash burn GLOBAL EXPANSION PLANS ON TR
Slide 14: Ambitions for Leading a New Paradigm in Preventive Cardiovascular Care
AMBITIONS for Leading a new paradigm in preventive cardiovascular care and growing our impact for patients globally AMARIN
Slide 15: Investor Presentation November 2022
Investor Presentation November 2022
Amarin Corp Plc\uk — Investor Presentation (November 2022) on 6ix